David Kaminsky, MD
Critical Care Medicine · Burlington, VTNPI 1134132913
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,950 of the $20,531 with a category attached, or 82.6%. Medical Graphics Corporation accounts for 86.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $6,359 and has fallen 50.1% since, to $3,176 in 2025.
Across 24 payments — averaging $855.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Graphics Corporation$18K
- Gyrus ACMI, Inc.$2K
- Spiration, Inc.$477
- AbbVie$101
Across 4 payments — averaging $6258.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$20K
- GSK$4K
- Acorda Therapeutics, Inc$568
What the payments were for
- Consulting fees$2,67713%
- Speaking & faculty fees$16,95083%
- Travel & lodging$490%
- Food & beverage$8544%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Graphics Corporation | 11 | $17,753 |
| Gyrus ACMI, Inc. | 6 | $2,200 |
| Spiration, Inc. | 6 | $477 |
| AbbVie | 1 | $101 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few critical care medicine providers in Vermontto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 35 | $180,894 |
| Fasenra PenBenralizumab | 16 | $77,620 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $68,136 |
| Spiriva RespimatTiotropium Bromide | 82 | $56,717 |
| Dupixent PenDupilumab | 12 | $43,648 |
| Serevent DiskusSalmeterol Xinafoate | 34 | $30,734 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $28,998 |
| Advair HfaFluticasone Propion/Salmeterol | 38 | $20,803 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $13,675 |
| Qvar RedihalerBeclomethasone Dipropionate | 30 | $10,742 |
| DuleraMometasone/Formoterol | 16 | $10,417 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $9,810 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $8,153 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $3,944 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $3,352 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Burlington
- Renee StapletonBurlington$10K
- John KlickBurlington$5K
- Katherine MensonBurlington$4K
- Katelin MorrissetteBurlington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.